Italian University Study Confirms E-Cigarettes' Effectiveness for Smoking Cessation

Dec.05.2024
Italian University Study Confirms E-Cigarettes' Effectiveness for Smoking Cessation
A recent evaluation by a research team from an Italian university shows that e-cigarettes are more effective than other methods in helping people quit smoking. The study notes that, although the long-term success rate of e-cigarettes is only 10%-12%, their potential warrants further research and integration into public health policies.

According to Catania Today's report on December 5th, a recent assessment conducted by the CoEHAR research team at the University of Catania showed that e-cigarettes are more effective than other methods in helping people quit smoking.

 

The study was published in the journal Drug and Alcohol Dependence, evaluating 16 systematic reviews covering data from 24 randomized controlled trials (RCTs).

 

"We believe the data from our review can support the integration of harm reduction strategies into public health policies in many countries," said Renée O'Leary, the first author of the review. 

 

"However, the review also highlights a critical gap in existing cessation strategies, with long-term success rates for e-cigarettes still modest, at 10%-12%, and insufficient research on relapse rates. New treatments and innovative approaches are needed."

 

Riccardo Polosa, co-author of the study and founder of CoEHAR, added: "This study provides solid evidence supporting the potential of modified-risk devices as an effective tool for smoking cessation, but it also calls attention to the need for better clinical guidelines and further analysis of long-term outcomes."

 

Riccardo Polosa, co-author of the study and founder of CoEHAR, added: "This study provides solid evidence supporting the potential of modified-risk devices as an effective tool for smoking cessation, but it also calls attention to the need for better clinical guidelines and further analysis of long-term outcomes."

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Heno Biotech Releases 2024 ESG Report at Inter Tabac, Setting a New Global Benchmark for the Nicotine Industry Through Green Development and Compliance Governance
Heno Biotech Releases 2024 ESG Report at Inter Tabac, Setting a New Global Benchmark for the Nicotine Industry Through Green Development and Compliance Governance
At InterTabac, the world’s largest tobacco industry exhibition in Dortmund, Germany, Heno Biotech released its 2024 Environmental, Social, and Governance (ESG) Report. As a leading enterprise in China’s natural nicotine sector, Heno presented its third consecutive annual ESG disclosure, highlighting achievements in green development, compliance governance, and social responsibility, setting a new benchmark for sustainable growth in the industry.
Sep.18
German Federal Council calls for ban on disposable vape, government resists change
German Federal Council calls for ban on disposable vape, government resists change
Germany's Federal Council calls for ban on disposable e-cigarettes due to environmental and economic threats, sparking debate.
Oct.14 by 2FIRSTS.ai
Tasmania, Australia Will Introduce New Laws Targeting Illegal Vape and Tobacco Retailers
Tasmania, Australia Will Introduce New Laws Targeting Illegal Vape and Tobacco Retailers
Tasmania will introduce new laws next year to tackle the illegal trade in tobacco and vapes. The legislation will strengthen penalties, allow inspectors to issue on-the-spot fines and shut down non-compliant retailers, and enhance coordination between police and health authorities.
Nov.11 by 2FIRSTS.ai
JTI launches Ploom AURA new heated tobacco device device in Romania
JTI launches Ploom AURA new heated tobacco device device in Romania
Japan Tobacco International(JTI) introduces Ploom AURA in Romania, combining SMART HEATFLOW technology to preserve tobacco flavor, aiming at high-end consumers.
Oct.17 by 2FIRSTS.ai
Nova Scotia, Canada: 16% of Residents Vape; Local E-Liquids and Disposable Products in High Demand
Nova Scotia, Canada: 16% of Residents Vape; Local E-Liquids and Disposable Products in High Demand
The latest data show that in 2024, disposable vape sales in Nova Scotia grew by 25%, and about 16% of residents use vaping products—signaling strong demand for tobacco alternatives. The province’s regulatory framework is forcing retailers to accelerate product-line adjustments and compliance upgrades.
Sep.23 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai